Caplin Steriles, a subsidiary of Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742) has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for the Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution.
The drug (eye drops) is a generic therapeutic equivalent version of Abbvie Inc.'s reference-listed drug COMBIGAN, according to a Wednesday filing to the Indian stock exchanges.
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is used for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.
As per IQVIATM estimates, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had sales of around $242 million for the 12 months ending December 2024 in the US.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。